{"entity":{"id":"nct05429463","kind":"trial","name":"Neoadjuvant Therapy of Sintilimab Combined With Chemotherapy for Resectable Squamous Cell NSCLC（neoSCORE II）","aka":["neoSCORE II"],"tldr":"A phase 3 trial of sintilimab, carboplatin and nab-paclitaxel in lung cancer, run by Second Affiliated Hospital, Zhejiang University, School of Medicine, now recruiting.","summary":"Neoadjuvant Therapy of Sintilimab Combined With Chemotherapy for Resectable Squamous Cell NSCLC（neoSCORE II） is a phase 3, randomised interventional study registered as NCT05429463 by Second Affiliated Hospital, Zhejiang University, School of Medicine, with a registry enrolment figure of 250 participants, started 2022-11-11 and due to reach its primary completion in 2025-11-11. Interventions recorded: Sintilimab; Carboplatin; Albumin-Bound Paclitaxel. Conditions listed: Squamous Cell Non-small Cell Lung Cancer. Primary outcome: Major pathological response rate (MPR). Lung eligibility wording from the registry: \"Squamous Cell Non-small cell lung cancer confirmed by cytology or histology\". Sites: China. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-25","links":[{"label":"ClinicalTrials.gov NCT05429463","url":"https://clinicaltrials.gov/study/NCT05429463"}],"tags":["ctgov-ingest","lung-deep-dive"],"related":[],"cancers":["resectable-nsclc"],"sections":[],"technologies":["checkpoint-inhibitor","cytotoxic-chemotherapy","platinum"],"targets":[],"drugs":["sintilimab","carboplatin","nab-paclitaxel"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT05429463","phase":"3","setting":"Neoadjuvant Therapy of Sintilimab Combined With Chemotherapy for Resectable Squamous Cell NSCLC（neoSCORE II）：A Prospective, Randomized, Open-Label, Multi-Center Phase 3 Trial","sponsor":"Second Affiliated Hospital, Zhejiang University, School of Medicine","enrolled":250,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct05429463/","neighbours":{"cancer":[{"id":"resectable-nsclc","kind":"cancer","name":"Resectable stage I to III non-small-cell lung cancer","route":"/cancers/resectable-nsclc/"}],"technology":[{"id":"cytotoxic-chemotherapy","kind":"technology","name":"Cytotoxic chemotherapy","route":"/technologies/cytotoxic-chemotherapy/"},{"id":"checkpoint-inhibitor","kind":"technology","name":"Immune checkpoint inhibitors","route":"/technologies/checkpoint-inhibitor/"},{"id":"platinum","kind":"technology","name":"Platinum agents","route":"/technologies/platinum/"}],"drug":[{"id":"carboplatin","kind":"drug","name":"Carboplatin","route":"/drugs/carboplatin/"},{"id":"nab-paclitaxel","kind":"drug","name":"Nab-paclitaxel","route":"/drugs/nab-paclitaxel/"},{"id":"sintilimab","kind":"drug","name":"Sintilimab","route":"/drugs/sintilimab/"}],"term":[{"id":"lung-trials-open-today","kind":"term","name":"Lung cancer trials open today (registry snapshot)","route":"/terms/lung-trials-open-today/"}]}}